/
HUMA
$0.80+$0.09 (+12.74%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$191.1M
270M shares
52-week range
$0.55 – $2.84
11% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
11.89%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-11.40
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $6.2M | $1.5M | $1.3M | $1.6M | $0 | $0 | $2.0M |
| Cost of revenue | $75.6M | $54.1M | $61.3M | $8.3M | $76.5M | $7.2M | $17.0M |
| Gross profit | −$69.4M | −$52.6M | −$60.1M | −$6.7M | −$76.5M | −$7.2M | −$15.0M |
| Gross margin | -1122.0% | -3527.0% | -4756.8% | -427.5% | — | — | -736.5% |
| R&D | $75.6M | $54.1M | $61.3M | $63.3M | $76.5M | $88.6M | $69.3M |
| Operating income | −$85.7M | −$64.6M | −$81.2M | −$84.6M | −$100.0M | −$114.4M | −$107.4M |
| EBITDA | −$78.9M | −$56.2M | −$13.9M | $2.4M | −$96.5M | −$132.2M | −$22.2M |
| Net income | −$85.4M | −$66.5M | −$26.5M | −$12.0M | −$110.8M | −$148.7M | −$40.8M |
| Net margin | -1380.7% | -4461.7% | -2096.4% | -764.5% | — | — | -2003.6% |
| EPS (diluted) | -4.25 | -5.52 | -0.66 | -0.12 | -1.07 | -1.26 | -0.26 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6M | $-0.34 | $-0.37–$-0.32 | 3 |
| 2027 | $26M | $-0.25 | $-0.27–$-0.23 | 3 |
| 2028 | $119M | $-0.03 | $-0.14–$0.11 | 4 |
| 2029 | $232M | $0.10 | $0.05–$0.16 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Humacyte, Inc. Common Stock
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
www.humacyte.com- Employees
- 184
- IPO / List date
- Aug 27, 2021
- HQ
- DURHAM, NC
Held by traders on TradeandTell
No one on the platform currently holds HUMA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-06-30 | 600,300 | $2.9M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded HUMA yet.
